Hepatitis Monthly

Published by: Kowsar

Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users

Seyed-Moayed Alavian 1 , 2 , Alireza Mirahmadizadeh 3 , Mehdi Javanbakht 4 , Ali Keshtkaran 5 , Alireza Heidari 5 , Atefeh Mashayekhi 6 , Shima Salimi 2 and Mohammad Hadian 6 , *
Authors Information
1 Baqiatallah Research Center for Gastrointestinal and Liver Diseases, Baqiatallah University of Medical Sciences, Tehran, IR Iran
2 Middle East Liver Disease Center, Tehran, IR Iran
3 HIV/AIDS Research center, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Health Management and Economics Research Center, School of Health Management and Information Sciences, Tehran University of Medical Sciences, Tehran, IR Iran
5 Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, IR Iran
6 Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: August 01, 2013, 13 (8); e12411
  • Published Online: August 17, 2013
  • Article Type: Research Article
  • Received: May 22, 2013
  • Revised: June 29, 2013
  • Accepted: July 15, 2013
  • DOI: 10.5812/hepatmon.12411

To Cite: Alavian S, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, et al. Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users, Hepat Mon. 2013 ; 13(8):e12411. doi: 10.5812/hepatmon.12411.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. J Viral Hepat. 2007; 14(8): 570-6[DOI][PubMed]
  • 2. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48(2): 418-31[DOI][PubMed]
  • 3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10): 705-14[PubMed]
  • 4. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997; 26(3 Suppl 1): 15S-20S[DOI][PubMed]
  • 5. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4): 1333-1342
  • 6. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007; 18(5): 352-8[DOI][PubMed]
  • 7. Kheirandish P, SeyedAlinaghi SA, Jahani M, Shirzad H, Ahmadian MS, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. Journal of Urban Health. 2009; 86(6): 902-908
  • 8. Alavian SM, Ahmadzad-Asl M, Bagheri Lankarani K, Shahbabaie MA, Bahrami Ahmadi A, Kabir A. Hepatitis C infection in the general population of Iran: a systematic review. Hepat Mon. 2009; 9(3): 211-23
  • 9. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. International Journal of Infectious Diseases. 2010; 14
  • 10. Nokhodian Z, Meshkati M, Adibi P, Ataei B, Kassaian N, Yaran M, et al. Hepatitis C among Intravenous Drug Users in Isfahan, Iran: a Study of Seroprevalence and Risk Factors. Int J Prev Med. 2012; 3-8[PubMed]
  • 11. Alavian SM, Fallahian F. Epidemiology of Hepatitis C in Iran and the World. Shiraz E Medical Journal. 2009; 10(4): 162-172
  • 12. Nasirian M, Doroudi F, Gooya MM, Sedaghat A, Haghdoost AA. Modeling of human immunodeficiency virus modes of transmission in iran. Journal of research in health sciences. 2012; 12(2): 81-87
  • 13. Rehle D, Leleux D, Erdelyi M, Tittel F, Fraser M, Friedfeld S. Ambient formaldehyde detection with a laser spectrometer based on difference-frequency generation in PPLN. Appl Phys B. 2001; 72(8): 947-52[PubMed]
  • 14. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. CMAJ. 2008; 179(11): 1143-51[DOI][PubMed]
  • 15. De Carli G, Puro V, Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection. 2003; 31 Suppl 2: 22-7[PubMed]
  • 16. Vickerman P, Hickman M, Judd A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol. 2007; 36(2): 396-405[DOI][PubMed]
  • 17. Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013; 57(3): 881-9[DOI][PubMed]
  • 18. Wejstål Rune. Sexual transmission of hepatitis C virus. Journal of hepatology. 1999; 31: 92-95
  • 19. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004; 82(6): 454-61[PubMed]
  • 20. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002; 1
  • 21. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007; 18(5): 359-63[DOI][PubMed]
  • 22. Kassaian N, Ataei B, Yaran M, Babak A, Shoaei P. Hepatitis B and C among women with illegal social behavior in Isfahan, Iran: Seroprevalence and associated factors. Hepat Mon. 2011; 11(5): 368-71[PubMed]
  • 23. Nokhodian Z, Yazdani MR, Yaran M, Shoaei P, Mirian M, Ataei B, et al. Prevalence and Risk Factors of HIV, Syphilis, Hepatitis B and C Among Female Prisoners in Isfahan, Iran. Hepat Mon. 2012; 12(7): 442-7[DOI][PubMed]
  • 24. Nelson Paul K, Mathers Bradley M, Cowie Benjamin, Hagan Holly, Des Jarlais Don, Horyniak Danielle, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. The Lancet. 378(9791): 571-583[DOI]
  • 25. Gibson David R, Flynn Neil M, McCarthy John J. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 1999; 13(14): 1807-1818
  • 26. Gowing Linda, Farrell Michael F, Bornemann Reinhard, Sullivan Lynn E, Ali Robert. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011; 8
  • 27. Gowing LR, Hickman M, Degenhardt L. Mitigating the risk of HIV infection with opioid substitution treatment. Bull World Health Organ. 2013; 91(2): 148-9[DOI][PubMed]
  • 28. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999; 281(11): 1000-5[PubMed]
  • 29. Watkins KE, Metzger D, Woody G, McLellan AT. High-risk sexual behaviors of intravenous drug users in- and out-of-treatment: implications for the spread of HIV infection. Am J Drug Alcohol Abuse. 1992; 18(4): 389-98[PubMed]
  • 30. Alary Michel, Joly Jean R, Vincelette Jean, Lavoie René, Turmel Bruno, Remis Robert S. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. American Journal of Public Health. 2005; 95(3): 502-505
  • 31. Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol. 2004; 33(1): 182-8[DOI][PubMed]
  • 32. Marincovich B, Castilla J, del Romero J, Garcia S, Hernando V, Raposo M, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect. 2003; 79(2): 160-2[PubMed]
  • 33. Roy E, Haley N, Leclerc P, Boivin JF, Cedras L, Vincelette J. Risk factors for hepatitis C virus infection among street youths. CMAJ. 2001; 165(5): 557-60[PubMed]
  • 34. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005; 100(6): 820-8[DOI][PubMed]
  • 35. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011; 204(1): 74-83[DOI][PubMed]
  • 36. Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect. 2004; 132(4): 699-708[PubMed]
  • 37. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011; 106(11): 1978-88[DOI][PubMed]
  • 38. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 1998; 317(7156): 433-7[PubMed]
  • 39. Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction. 1997; 92(8): 999-1005[PubMed]
  • 40. Macalino GE, Celentano DD, Latkin C, Strathdee SA, Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev. 2002; 14(5): 367-78[PubMed]
  • 41. Novick David M, Richman Beverly L, Friedman Jeffrey M, Friedman Jacqueline E, Fried Christine, Wilson Janifer P, et al. The medical status of methadone maintenance patients in treatment for 11–18 years. Drug and Alcohol Dependence. 1993; 33(3): 235-245[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments